Teva Pharmaceutical Industries Limited [NYSE: TEVA] stock went on an upward path that rose over 1.75% on Friday, amounting to a one-week price decrease of less than -6.25%. The company report on July 1, 2021 that Teva to Host Conference Call to Discuss Second Quarter 2021 Financial Results at 8 a.m. ET on July 28, 2021.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that it will issue a press release on its financial results for the second quarter of 2021 on Wednesday, July 28, 2021 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
In order to participate, please dial the following numbers: United States 1-877-870-9135; Israel 1-809-213-985 or International +44 (0) 2071 928338; passcode: 9693275.
Over the last 12 months, TEVA stock dropped by -19.90%. The one-year Teva Pharmaceutical Industries Limited stock forecast points to a potential upside of 21.98. The average equity rating for TEVA stock is currently 2.90, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $10.10 billion, with 1.10 billion shares outstanding and 1.09 billion shares in the current float. Compared to the average trading volume of 8.05M shares, TEVA stock reached a trading volume of 7565600 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Teva Pharmaceutical Industries Limited [TEVA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TEVA shares is $11.92 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TEVA stock is a recommendation set at 2.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Teva Pharmaceutical Industries Limited shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 04, 2021. While these analysts kept the previous recommendation, RBC Capital Mkts raised their target price to Sector Perform. The new note on the price target was released on April 07, 2021, representing the official price target for Teva Pharmaceutical Industries Limited stock. On August 06, 2020, analysts increased their price target for TEVA shares from 10 to 13.
The Average True Range (ATR) for Teva Pharmaceutical Industries Limited is set at 0.28, with the Price to Sales ratio for TEVA stock in the period of the last 12 months amounting to 0.62. The Price to Book ratio for the last quarter was 1.02, with the Price to Cash per share for the same quarter was set at 1.60.
TEVA Stock Performance Analysis:
Teva Pharmaceutical Industries Limited [TEVA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.25. With this latest performance, TEVA shares dropped by -13.33% in over the last four-week period, additionally sinking by -15.99% over the last 6 months – not to mention a drop of -19.90% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TEVA stock in for the last two-week period is set at 32.20, with the RSI for the last a single of trading hit 27.39, and the three-weeks RSI is set at 36.08 for Teva Pharmaceutical Industries Limited [TEVA]. The present Moving Average for the last 50 days of trading for this stock 10.40, while it was recorded at 9.44 for the last single week of trading, and 10.45 for the last 200 days.
Insight into Teva Pharmaceutical Industries Limited Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Teva Pharmaceutical Industries Limited [TEVA] shares currently have an operating margin of +18.36 and a Gross Margin at +46.38. Teva Pharmaceutical Industries Limited’s Net Margin is presently recorded at -23.95.
Return on Total Capital for TEVA is now 7.87, given the latest momentum, and Return on Invested Capital for the company is -11.37. Return on Equity for this stock declined to -34.11, with Return on Assets sitting at -7.60. When it comes to the capital structure of this company, Teva Pharmaceutical Industries Limited [TEVA] has a Total Debt to Total Equity ratio set at 263.30. Additionally, TEVA Total Debt to Total Capital is recorded at 72.47, with Total Debt to Total Assets ending up at 52.13. Long-Term Debt to Equity for the company is recorded at 231.50, with the Long-Term Debt to Total Capital now at 63.72.
Reflecting on the efficiency of the workforce at the company, Teva Pharmaceutical Industries Limited [TEVA] managed to generate an average of -$345,488 per employee. Receivables Turnover for the company is 3.34 with a Total Asset Turnover recorded at a value of 0.32.Teva Pharmaceutical Industries Limited’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 1.00.
TEVA Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TEVA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Teva Pharmaceutical Industries Limited go to 5.77%.
Teva Pharmaceutical Industries Limited [TEVA] Insider Position Details
There are presently around $5,329 million, or 52.20% of TEVA stock, in the hands of institutional investors. The top three institutional holders of TEVA stocks are: CAPITAL RESEARCH GLOBAL INVESTORS with ownership of 128,693,223, which is approximately -1.112% of the company’s market cap and around 1.05% of the total institutional ownership; CAPITAL WORLD INVESTORS, holding 53,020,773 shares of the stock with an approximate value of $493.09 million in TEVA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $397.94 million in TEVA stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Teva Pharmaceutical Industries Limited stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 182 institutional holders increased their position in Teva Pharmaceutical Industries Limited [NYSE:TEVA] by around 41,890,592 shares. Additionally, 187 investors decreased positions by around 46,639,912 shares, while 123 investors held positions by with 484,428,703 shares. The mentioned changes placed institutional holdings at 572,959,207 shares, according to the latest SEC report filing. TEVA stock had 57 new institutional investments in for a total of 4,570,266 shares, while 46 institutional investors sold positions of 6,769,208 shares during the same period.